Notably, combination therapy still achieved significant anti-tumor efficacy at the lower doses of PD-1 therapy (66 μg and 22 μg), whereas PD-1 blockade alone had little impact on tumor burden (Fig 4A). This evidence concerns the gene PDCD1 and neoplasm.